Eidos Therapeutics, Inc. (EIDX) financial statements (2020 and earlier)

Company profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments191166131147157167177
Cash and cash equivalents191166131147157167177
Receivables0000000
Other undisclosed current assets5542232
Total current assets:196171136149159170179
Noncurrent Assets
Operating lease, right-of-use asset44  
Property, plant and equipment1100000
Other noncurrent assets3233100
Other undisclosed noncurrent assets  11   
Total noncurrent assets:8844100
TOTAL ASSETS:204179139153160170179
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5634243
Accounts payable3423222
Accrued liabilities0100001
Employee-related liabilities2111010
Debt10     
Deferred compensation liability0000000
Due to related parties0000001
Other undisclosed current liabilities4333221
Total current liabilities:101068565
Noncurrent Liabilities
Long-term debt and lease obligation215     
Long-term debt, excluding current maturities16      
Operating lease, liability55  
Liabilities, other than long-term debt1000000
Other liabilities0000000
Derivative instruments and hedges, liabilities1      
Other undisclosed noncurrent liabilities  11   
Total noncurrent liabilities:22511000
Total liabilities:321579566
Stockholders' equity
Stockholders' equity attributable to parent171164132144155164174
Common stock0000000
Additional paid in capital274248223221220215214
Accumulated deficit(103)(84)(91)(77)(65)(51)(41)
Total stockholders' equity:171164132144155164174
TOTAL LIABILITIES AND EQUITY:204179139153160170179

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues 27     
Cost of revenue
(Cost of Goods and Services Sold)
 (3)     
Gross profit: 24     
Operating expenses(19)(18)(15)(13)(10)(11)(9)
Other undisclosed operating income0      
Operating income (loss):(19)6(15)(13)(10)(11)(9)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
1111(1)0(1)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)   7  
Net income (loss) attributable to parent:(19)7(14)(12)(4)(10)(11)
Other undisclosed net income available to common stockholders, basic    1  
Net income (loss) available to common stockholders, diluted:(19)7(14)(12)(3)(10)(11)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(19)7(14)(12)(4)(10)(11)
Comprehensive income (loss), net of tax, attributable to parent:(19)7(14)(12)(4)(10)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: